HIGHLIGHTS
- who: Wenhao Xu from the Jiaotong University, China have published the research: Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma, in the Journal: (JOURNAL)
- what: The study has essential implications for the design and analysis of molecular epidemiology studies in patients with sarcomatoid differentiation of RCC as well as the somatic characterization of genomes for the Chinese population.
SUMMARY
Meanwhile, the JAVELIN Renal 101 trial enrolled 108 RCC patients with sarcomatoid histology (47 patients in the avelumab . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.